Business
Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal Monoclonal Antibody Foralumab
--News Direct--By Rachael Green, BenzingaThis month, Tiziana Life Sciences (NASDAQ: TLSA) expects to start enrolling patients for a phase 2a trial of
About this update from Tiziana Life Sciences Ltd
[{"type":"text","content":"--News Direct--By Rachael Green, BenzingaThis month, Tiziana Life Sciences (NASDAQ: TLSA) expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS) that’s administered through the nose. The news marks a major milestone on the path to bring the clinical-stage company’s lead drug candidate to market. MS Patients Have Few Effective Treatment Options, And SPMS Patients Have Even Fewer The incurable disease involves recurring painful flare-ups that can be so severe people lose the ability to walk or move. This happens when the immune system attacks parts of the body’s own central nervous system, damaging nerve fibers and interrupting communication between the brain and the rest of the body. The oral medications that are available are generally immune-suppressing drugs that can reduce relapse rates. But because they are typically a blanket suppressant of the immune system, they also generally come with harmful side effects and increased risk of infection. Moreover, they aren’t always effective for patients with non-active secondary progressive MS (SPMS), the more severe and difficult-to-treat form of the disease that Tiziana is developing Foralumab for.When a flare-up strikes, the current standard of care for MS generally involves either intravenous corticosteroids for reducing inflammation or blood plasma exchange – both of which need to be done in a hospital. Positive 6-Month Clinical Results Give Hope That Foralumab Could Make A Difference In Patients’ LivesForalumab is an anti-CD3 monoclonal antibody. It binds to the CD3 receptor on the surface of T cells in the patient’s immune system. Rather than a blanket immune suppressor, this mechanism of action selectively dampens the autoimmune response — when the T cells attack the body’s own cells — without disrupting its ability to detect and fight external pathogens. This has made it a promising candidate for fighting autoimmune diseases like MS as it has the potential to prevent painful autoimmune attacks without the severe side effects and risks that come with other immune-suppressing drugs.Tiziana reports that Foralumab is the only anti-CD3 monoclonal antibody therapy currently in development that is fully human, meaning it's even less likely to trigger adverse reactions than the genetically...